Clinical implications of neuropharmacogenetics

Corvol, Jean-Christophe; DEVOS, DAVID; Hulot, J. -S.; Lacomblez, Lucette

Type de document :

Article dans une revue scientifique: Article original

DOI :

10.1016/j.neurol.2015.04.003

PMID :

26008819

URL permanente :

http://hdl.handle.net/20.500.12210/15897

Titre :

Clinical implications of neuropharmacogenetics

Auteur(s) :

Corvol, Jean-Christophe [Auteur]
DEVOS, DAVID [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U1171
Lille Neurosciences & Cognition (LilNCog) - U 1172
Hulot, J. -S. [Auteur]
Lacomblez, Lucette [Auteur]

Titre de la revue :

Revue neurologique

Nom court de la revue :

Rev. Neurol.

Numéro :

171

Pagination :

482-497

Date de publication :

2015-06-01

ISSN :

0035-3787

Mot(s)-clé(s) en anglais :

Genetic
Pharmacogenetic
Neurology

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: Pharmacogenetics aims to identify the underlying genetic factors participating in the variability of drug response. Indeed, genetic variability at the DNA or RNA levels can directly or indirectly modify the ...
Lire la suite >BACKGROUND: Pharmacogenetics aims to identify the underlying genetic factors participating in the variability of drug response. Indeed, genetic variability at the DNA or RNA levels can directly or indirectly modify the pharmacokinetic or the pharmacodynamic parameters of a drug. The ultimate aim of pharmacogenetics is to move towards a personalised medicine by predicting responders and non-responders, adjusting the dose of the treatment, and identifying individuals at risk of adverse drug effects. METHODS: A literature research was performed in which we reviewed all pharmacogenetic studies in neurological disorders including neurodegenerative diseases, multiple sclerosis, stroke and epilepsy. RESULTS: Several pharmacogenetic studies have been performed in neurology, bringing insights into the inter-individual drug response variability and in the pathophysiology of neurological diseases. The principal implications of these studies for the management of patients in clinical practice are discussed. CONCLUSIONS: Although several genetic factors have been identified in the modification of drug response in neurological disorders, most of them have a marginal predictive effect at the single gene level, suggesting mutagenic interactions as well as other factors related to drug interaction and disease subtypes. Most pharmacogenetic studies deserve further replication in independent populations and, ideally, in pharmacogenetic clinical trials to demonstrate their relevance in clinical practice.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Troubles cognitifs dégénératifs et vasculaires

Date de dépôt :

2019-11-27T13:02:08Z
2020-02-19T12:42:31Z
2022-10-21T15:36:14Z
2022-10-21T16:04:32Z

Fichiers

document
Accès libre
Accéder au document

Historique des modifications

Numéro de version	Lien	Date de modification
4	20.500.12210/15897*	2022-10-21T16:03:57Z
3	20.500.12210/15897.3	2022-10-21T15:35:53Z
2	20.500.12210/15897.2	2020-02-19T12:39:57Z

*Version sélectionnée

Clinical implications of neuropharmacogenetics BibTeX CSV Excel RIS

Fichiers

Historique des modifications

Clinical implications of neuropharmacogenetics

BibTeX

CSV

Excel

RIS